SCHEMBL7072046

SCHEMBL7072046

CO[C@@H]1O[C@H](C(=O)NNC(=S)NCc2ccccc2)[C@@H]2OC(C)(C)O[C@@H]12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.51
▸ GAA P10253 5/20 0.43
▸ ALOX12 P18054 2/20 0.43
▸ ALPL P05186 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ POLB P06746 3/20 0.43
▸ LMNA P02545 3/20 0.42
▸ ADAMTS5 Q9UNA0 2/20 0.42
▸ MAPT P10636 2/20 0.42
▸ NPC1 O15118 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ CA1 P00915 2/20 0.41
▸ CA9 Q16790 2/20 0.41
▸ MEN1 O00255 3/20 0.40
▸ KMT2A Q03164 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7072042 1.00 ALDH1A1 (0.51) ALDH1A1GAAALOX12ALPLHPGD
SCHEMBL7214820 0.82 CPB1 (0.40) ALDH1A1SMN1; SMN2LMNANPC1CYP1A2
SCHEMBL7214815 0.82 CPB1 (0.40) ALDH1A1SMN1; SMN2LMNANPC1CYP1A2
SCHEMBL7072036 0.76 KMT2A (0.33) ALDH1A1ALOX12LMNACYP2C9NPSR1
SCHEMBL5408623 0.71 CA2 (0.39) ALDH1A1MAPTCYP2C9MEN1KMT2A
SCHEMBL4370834 0.71 CA2 (0.39) ALDH1A1MAPTCYP2C9MEN1KMT2A
SCHEMBL6575029 0.70 CA2 (0.38) ALDH1A1MAPTCYP2C9MEN1KMT2A
SCHEMBL7038325 0.69 GSTP1 (0.40) ALDH1A1TDP1
SCHEMBL7213941 0.68 CA2 (0.43) ALDH1A1MAPTCYP2C9NPSR1MEN1
SCHEMBL12150033 0.68 TSHR (0.48) ALDH1A1GAAHPGDSMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6624158-B2 Compound for use in the treatment of; sepsis, urogential, psychological, nervous system, respiratory, inflammatory, skin vascular and arthritic; wound healing agents PFIZER INC 2003-09-23 — — US disclosed
EP-1317465-A1 PURINE DERIVATIVES PFIZER INC. (US) 2003-06-11 — — EP disclosed
US-20020072597-A1 Purine derivatives PFIZER INC. 2002-06-13 — — US disclosed
WO-2002022630-A1 PURINE DERIVATIVES PFIZER LIMITED (GB) 2002-03-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020072597-A1 Purine derivatives ADORA2A, ADORA1, ADORA3 ALDH1A1 226/4885GAA 2851/4885ALOX12 826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback